Syneron Medical Ltd. (NASDAQ:ELOS)
The Company designs, develops and markets innovative aesthetic medical products based on its ELOS, technology, which uses the synergy between electrical energy and optical energy to provide effective, safe and affordable aesthetic medical treatments.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
This former Rule Breaker has bounced back pretty well from our sell recommendation in 2009. It has a lot of cash (always did), so the underlying business isn't priced for much. I'll rejoin the fray on this one and give it another green thumb. Please note, this may be a contrary indicator: I struck out in my first at-bat with ELOS.
Recs
Just hit the 100 mva on the daily 1 year chart. May close the gap at the 11.70 area. Expect buyers around this. Undervalued, with some brokers targeting $17.25
Recs
Good earnings.
Recs
stock of the day
Recs
It's profits are shrinking that's just not a good sign long term.
Recs
Stock is trading just above cash but there is significant macro pressure on elective surgery, plus competition from Cutera, Cynosure and Candela. There's a reason all 4 stocks are trading at enterprise value, because all 4 aren't going to make it through this recession.
Recs
bravobevo
Recs
Great growth and future earnings.
Recs
Medical technology good long-term value.
Recs
Sells at cash value. Are you kidding?
Recs
Deep value play for a number of prominent investors has become an even deeper value after recent earnings miss. Sub $10 looks like good entry point - technicals suggest we are nearing short-term bottom, while value metrics seem compelling - debt free, 60% of market cap in cash, small premium to book. Likely dead money for a while, but solid 3-5 year recovery prospects from current level.
Recs
Still a way to go...down. Not a buy...yet.
Recs
Technical bottom, Fantastic balance sheet, net income to sales ratio is high (20 to 50%), no capital needed to grow, tiny depreciation charge, some great and famous individual investors are accumulating it. What I call a growth company at a value price.
Recs
People might not be too excited about spending more money on their products, while the credit card debt, mortgage, prices in general are all increasing. Also, more people are losing their jobs. Might be best to stay away from these stocks for now.
Recs
This company has solid fundamentals. Low Price to book ratio. Low debt to equity and solid earnings. In this bear market you need whatever good companies you can find.
Recs
You gotta love a BEAR market. There are so many great stocks trading at levels I usually only dream about. Not much of a downside here. Expect a minimum of a 50% return, but closer to 75-100%. Dont b fooled fools, this is know value trap. 0 debt and mgmt buying back shares.
Recs
I've held this stock since before the October plunge...I do think it was overdone. The company still seems well-managed. The larger trend of an aging population bodes well for its product line, though the near-term economic uncertainty might make customers a bit hesitant.
Recs
because I am putting my money where my mouth is.
Recs
Important to note that insurances are covering/reimbursing certain procedures!
Recs
Safety & hi growth potential
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 99 : 1 2 3 4 5 Next »